Introduction The risk of cardiovascular outcomes associated with gestational hypertension is unclear. This study aimed to quantify the association between gestational hypertension and cardiovascular outcomes for women.

Design Systematic review and meta-analysis.

Data Sources PubMed, Embase and Web of Science.

Eligibility Criteria Studies examining the association between gestational hypertension and any cardiovascular outcome, including cardiovascular disease, coronary heart disease, stroke and heart failure. Two reviewers independently assessed the abstracts and full-text articles. Study characteristics and the relative risk of cardiovascular outcomes associated with gestational hypertension, therefore more research is needed to assess the presence of a dose-response relationship.

Conflict of Interest None

Results Nineteen studies involving 3,601,192 women (128,445 with gestational hypertension) were identified. A history of one or more pregnancies affected by gestational hypertension was associated with an increased risk of cardiovascular disease (12 studies, relative risk 1.73, 95% confidence interval: 1.43–2.08), coronary heart disease (8 studies, 1.56, 1.35–1.81) and heart failure (4 studies, 1.70, 1.43–2.02). Among the outcomes examined, the highest absolute risk increase was for cardiovascular disease: 14.0 events/1000 person-years. Associations between gestational hypertension and cardiovascular disease were broadly consistent across subgroups, although there was evidence that high quality studies with a low risk of bias had lower effect estimates. When analyses were restricted to high quality studies, an increased risk was found for all outcomes: cardiovascular disease, (1.53, 1.25–1.88); coronary heart disease, (1.40, 1.26–1.54); stroke, (1.35, 1.14–1.60); and heart failure, (1.70, 1.43–2.02).

Conclusion Gestational hypertension is associated with an increased risk of overall cardiovascular disease, coronary heart disease, stroke and heart failure. Only two studies evaluated risk associated with the number of pregnancies affected by gestational hypertension, therefore more research is needed to assess the presence of a dose-response relationship.

ESC RISK SCORE-ADJUSTED COST ANALYSIS OF THE INVESTIGATIONS IN STABLE CHEST PAIN: NICE VS. ESC GUIDELINES

Introduction National Institute for Health and Clinical Excellence (NICE) have removed the use of pre-test probability risk score (RS) in patients with new onset stable chest pain. They recommend computed tomography coronary angiography (CTCA) as first line investigation irrespective of RS. European Society of Cardiology (ESC) suggest using the ESC RS and recommend functional tests as initial investigation in patients with RS 15–85% and allow for the use of CTCA in patients with RS of 15–50%. We compare the two recommended strategies (NICE vs ESC) as applied in two neighbouring NHS Trusts in South London. We additionally investigate the prognostic role of ESC RS in terms of need for revascularization.

Methods Two groups of patients, who attended rapid access chest pain clinics in two neighbouring NHS Trusts were recruited. Group A (N = 667) were investigated based on ESC guidelines, whereas Group B (N = 654) were investigated following NICE guidance. The RS was calculated as per ESC recommendation based on patient age, gender and typicality of chest pain. The patients were divided in two subgroups according to ESC RS. Sub-groups A1 and B1, were of patients with lower RS (15–50%) and sub-groups A2 and B2 were of patients with higher RS (>50%). The need for invasive coronary angiography (ICA) and revascularization were compared between groups and sub-groups. A cost analysis was performed based on UK tariffs for CTCA (£220), stress echo (£176) and ICA (£1,001).
Abstract 109 Figure 1

Abstract 109 Figure 2

Abstract 109 Table 1

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
<th>p value</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>57.2 ± 12.2</td>
<td>56.9 ± 10.9</td>
<td>0.697</td>
<td>57.0 ± 11.5</td>
</tr>
<tr>
<td>Gender (male)</td>
<td>174 (49.9%)</td>
<td>240 (51.3%)</td>
<td>0.687</td>
<td>414 (50.7%)</td>
</tr>
<tr>
<td>ESC Risk Score</td>
<td>39.2 ± 21.3</td>
<td>41.1 ± 21.2</td>
<td>0.214</td>
<td>36.1 ± 21.0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>154 (44.1%)</td>
<td>199 (42.5%)</td>
<td>0.705</td>
<td>353 (43.2%)</td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>216 (61.9%)</td>
<td>264 (56.4%)</td>
<td>0.142</td>
<td>480 (58.8%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>79 (22.6%)</td>
<td>94 (20.1%)</td>
<td>0.403</td>
<td>173 (21.2%)</td>
</tr>
<tr>
<td>Family History</td>
<td>149 (42.7%)</td>
<td>184 (39.3%)</td>
<td>0.370</td>
<td>333 (40.8%)</td>
</tr>
<tr>
<td>Smoking</td>
<td>80 (22.9%)</td>
<td>88 (18.8%)</td>
<td>0.168</td>
<td>168 (20.6%)</td>
</tr>
<tr>
<td>ICA</td>
<td>77 (22.1%)</td>
<td>95 (20.3%)</td>
<td>0.608</td>
<td>172 (21.1%)</td>
</tr>
<tr>
<td>Revascularization</td>
<td>28 (8.0%)</td>
<td>41 (8.8%)</td>
<td>0.708</td>
<td>69 (8.4%)</td>
</tr>
</tbody>
</table>
Baseline characteristics and the prevalence of cardiovascular risk factors were similar between Groups A and B (Table 1). The rate of progression to ICA was comparable in the two groups (9.9% vs 12.6%; p=0.377), as was the rate of revascularization (4.0% vs 5.0%; p=0.532) (Figure 1). The average per investigated patient cost was lower in Group A by £46.11 (£279.66 vs £325.77).

In Group A1 there was a lower rate of progression to ICA compared to Group B1 (8.7% vs 12.6%, p=0.177) as was for revascularization (2.6% vs 5.5%, p=0.122). The average per patient cost was considerably lower in Group A1 by £69.54.

18.5% of patients proceeded to ICA in Group A2 compared to 14.6% in Group B2 (p=0.512) and 10.8% were revascularized as opposed to 5.2% (p=0.187). The average cost per investigated patient was slightly higher in Group A2 by £20.99.

Investigating possible predictors of revascularization (ESC RS, diabetes, family history of coronary artery disease, smoking, hypercholesterolaemia), only the ESC RS was found to be independently related to the need for revascularization (OR: 1.049, 95%CI: 1.036–1.062, p<0.001).

Conclusion Both NICE and ESC recommendations on new onset stable chest pain lead to similar rates of progression to ICA and revascularization, but lower cost when stress echo (ESC guidance) is used as first line investigation. There was no significant difference when we repeated the analysis in low and high ESC RS patients. However, the ESC RS was the only independent predictor of need for revascularization.

Conflict of Interest None

---

**CORNEAL BIOMECHANICAL PROPERTIES AND VASCULAR COMPLIANCE IN THE UK BIOBANK COHORT**


10.1136/heartjnl-2019-BCS.107

Introduction Intra-ocular pressure (IOP) measurement is an integral part of a comprehensive eye examination. In addition to IOP, corneal biomechanical characteristics such as corneal hysteresis (CH), a measurement of viscoelastic compliance, and corneal resistance factor (CRF), derived from corneal deformability, have also been identified as useful indicators of incidence and progression of primary open angle glaucoma (POAG) (1,2). Corneal tissue shares compositionally similar properties with arterial tissue (3,4). Our cross-sectional observational study aimed to ascertain whether corneal biomechanical metrics (CH & CRF) are associated with arterial stiffness – a well-established marker of future cardiovascular (CV) events and mortality.

Methods From an initial pool of 5065 participants from the community-based UK Biobank study, 4018 were rejected for missing data, leaving a cohort of 1047 individuals (male/female ratio: 0.496, mean age: 62 years, white ethnicity: 96.1%) (Table 1). Corneal biomechanical metrics (CH & CRF), were obtained using a Reichert Ocular Response Analyzer (ORA). Arterial compliance was quantified by aortic distensibility (AoD) derived by cardiovascular magnetic resonance (CMR) imaging. The relationship between corneal and vascular compliance parameters was assessed using both Spearman rank correlation coefficient analysis, and univariable and multivariable regression analyses adjusting for potential influential confounding variables – age, sex, ethnicity, height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), smoking status, regular alcohol intake, diabetes status and dyslipidaemia.

Results A significant weakly positive correlation was observed between CH and AoD at both the ascending aorta (AA) and proximal descending aorta (PDA) (AA: Rho = 0.08, p = 0.01; PDA: Rho = 0.11, p <0.01), however no significant correlation was observed between CRF and AoD.

In univariable analysis, only CH produced significant changes in AoD at both the AA and PDA (AA: β = +3.0% per 10% increase in CH, 95% CI = 0.6 to 5.5, p = 0.02; PDA: β = +2.6% per 10% increase in CH, 95% CI = 0.8 to 4.4, p = 0.004) (Figure 1). There was no significant linear relationship between CH or CRF and AoD in multivariable regression analysis, at both the AA and PDA (CH at AA: β = +0.8% per 10% increase in CH, 95% CI = -0.9 to 2.6, p = 0.37; CH at PDA: β = +0.8% per 10% increase in CH, 95% CI = -0.3 to 2.0, p = 0.16; CRF at AA: β = +1.3% per 10% increase in CH, 95% CI = -0.4 to 3.0, p = 0.13; CRF at PDA: β = +0.9% per 10% increase in CH, 95% CI = -0.3 to 2.0, p = 0.13).

Conclusion In this community-based cohort, we observed a weakly significant general correlation between CH and AoD. After adjustment for potential confounding factors, we then observed no significant relationship between corneal and aortic biomechanical indices, suggesting that in a general population, biomechanical corneal indices are not independently associated with parameters of central arterial compliance.

Conflict of Interest None